Pancreatic β-cell Autoantigen-Specific T Cell

Pancreatic β-cell autoantigen-specific T cells are a subset of T lymphocytes that recognize and respond to self-antigens (autoantigens) expressed by pancreatic β-cells. These cells play a central role in the pathogenesis of type 1 diabetes mellitus (T1DM), an autoimmune disease characterized by the immune-mediated destruction of insulin-producing β-cells in the islets of Langerhans. These autoreactive T cells, both CD4+ helper and CD8+ cytotoxic subsets, are activated when they encounter pancreatic β-cell antigens presented by antigen-presenting cells (APCs) via major histocompatibility complex (MHC) molecules. CD8+ T cells directly mediate cytotoxicity against β-cells through release of perforin, granzyme B, IFN-γ, and TNF-α, leading to apoptosis or necrosis of targeted β-cells. CD4+ T cells can differentiate into various effector phenotypes: Th1, Th17, and Regulatory T Cells (Tregs). Major autoantigens targeted by these pathogenic T cell populations include Insulin, GAD65, IA2/ICA512, and IA2β/phogrin. The presence and expansion of these autoantigen-specific T cell populations correlate with disease onset and serves as a biomarker for early diagnosis or risk assessment for type 1 diabetes. Immunotherapies aiming at modulating their activity are under investigation for prevention or treatment strategies.

Immunomodulation, deletion, anergy induction, regulatory enhancement